CA2396351A1 - New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders - Google Patents

New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders Download PDF

Info

Publication number
CA2396351A1
CA2396351A1 CA002396351A CA2396351A CA2396351A1 CA 2396351 A1 CA2396351 A1 CA 2396351A1 CA 002396351 A CA002396351 A CA 002396351A CA 2396351 A CA2396351 A CA 2396351A CA 2396351 A1 CA2396351 A1 CA 2396351A1
Authority
CA
Canada
Prior art keywords
antipsychotic
antipsychotic agent
dioxino
indol
benzylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002396351A
Other languages
French (fr)
Other versions
CA2396351C (en
Inventor
Karen Lovell Marquis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth
Karen Lovell Marquis
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth, Karen Lovell Marquis, American Home Products Corporation filed Critical Wyeth
Publication of CA2396351A1 publication Critical patent/CA2396351A1/en
Application granted granted Critical
Publication of CA2396351C publication Critical patent/CA2396351C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Therapeutic combinations useful in the treatment or prevention of psychotic disorders, to pharmaceutical compositions containing said combinations, and to their use in the treatment or prophylaxis of prevention disorders are provid ed.

Claims (26)

1. A composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetra-hydro-7H-1,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent.
2. A pharmaceutical composition comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one, an antipsychotic agent, and one or more pharmaceutical carriers therefor.
3. A pharmaceutical composition for treating a patient suffering from a psychotic disorder comprising an effective amount of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one, in combination with an effective amount of an antipsychotic agent.
4. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is an atypical antipsychotic.
5. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is a typical antipsychotic.
6. A composition according to any one of Claims 1 to 3 wherein the antipsychotic agent is selected from chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
7. A composition according to any one of Claims 1 to 6 wherein the composition is adapted for oral administration.
8. A composition according to any one of Claims 1 to 7 wherein the composition is adapted to administer the antipsychotic in the amount of about 10 mg to about 1000 mg per day.
9. A method of treating a patient suffering from a psychotic disorder comprising administering to said patient an effective amount of (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one, in combination with an effective amount of an antipsychotic agent.
10. The method of Claim 9 wherein the antipsychotic agent is an atypical antipsychotic.
11. The method of Claim 9 wherein the antipsychotic agent is a typical antipsychotic.
12. The method of Claim 9 wherein the antipsychotic agent is selected from the group consisting of chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
13. The method of any one of Claims 9 to 12 wherein administration of the compounds is oral.
14. The method of Claim 9 wherein the patient is suffering from schizophrenia.
15. The method of Claim 9 wherein the patient is suffering from schizoaffective disorder.
16. The method of Claim 9 wherein the patient is suffering from depression.
17. The method of Claim 9 wherein the antipsychotic is administered in the amount of about 10 mg to about 1000 mg per day.
18. A product comprising (S)-2-(benzylaminomethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent as a combined preparation for simultaneous, separate or sequential administration to treat a patient suffering from a psychotic disorder.
19. A product according to Claim 18 wherein the antipsychotic agent is an atypical antipsychotic.
20. A product according to Claim 18 wherein the antipsychotic agent is a typical antipsychotic.
21. A product according to Claim 18 wherein the antipsychotic agent is selected from chlorpromazine, mesoridazine, thioridazine, fluphenazine, trifluoperazine, perphenazine, clozapine, haloperidol, loxapine, molindone, thiothixene, risperidone, seroquel, and olanzapine.
22. A product according to any one of Claims 18 to 21 which is adapted for oral administration.
23. A product according to Claim 18 for treating schizophrenia.
24. A product according to Claim 18 for treating schizoaffective disorder.
25. A product according to Claim 18 for treating depression.
26. A patient pack comprising at least one active ingredient selected from (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and an antipsychotic agent, and comprising an information insert containing directions on the use of the active ingredient or active ingredients in a combination comprising (S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]-indol-8-one and an antipsychotic.
CA002396351A 1999-12-10 2000-12-07 New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders Expired - Lifetime CA2396351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10
PCT/US2000/033060 WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Publications (2)

Publication Number Publication Date
CA2396351A1 true CA2396351A1 (en) 2001-06-14
CA2396351C CA2396351C (en) 2009-11-10

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396351A Expired - Lifetime CA2396351C (en) 1999-12-10 2000-12-07 New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders

Country Status (20)

Country Link
EP (1) EP1235570A2 (en)
JP (1) JP5557409B2 (en)
KR (1) KR100772854B1 (en)
CN (1) CN1230164C (en)
AR (1) AR026756A1 (en)
AU (1) AU784211B2 (en)
BR (1) BR0016168A (en)
CA (1) CA2396351C (en)
CZ (1) CZ20021880A3 (en)
EA (1) EA005002B1 (en)
HK (1) HK1045942A1 (en)
HU (1) HUP0203309A3 (en)
IL (2) IL149669A0 (en)
MX (1) MXPA02005649A (en)
NO (1) NO20022739L (en)
NZ (1) NZ519381A (en)
PL (1) PL355292A1 (en)
TW (1) TWI222864B (en)
WO (1) WO2001041750A2 (en)
ZA (1) ZA200205484B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5547865B2 (en) 2003-10-29 2014-07-16 ワイス・エルエルシー Sustained release pharmaceutical composition comprising aprindole and its derivatives
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
MX2010008875A (en) * 2008-02-13 2010-08-31 Targacept Inc Combination of alpha 7 nicotinic agonists and antipsychotics.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (en) * 1995-03-16 1999-12-06 大塚製薬 株式会社 Method for producing carbostyril derivative
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
ZA200205484B (en) 2003-12-31
TWI222864B (en) 2004-11-01
JP5557409B2 (en) 2014-07-23
PL355292A1 (en) 2004-04-05
KR20030016207A (en) 2003-02-26
NO20022739D0 (en) 2002-06-07
CN1230164C (en) 2005-12-07
EA200200656A1 (en) 2002-12-26
HUP0203309A2 (en) 2003-01-28
AR026756A1 (en) 2003-02-26
WO2001041750A3 (en) 2002-02-14
MXPA02005649A (en) 2004-09-10
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
BR0016168A (en) 2002-08-20
EA005002B1 (en) 2004-10-28
HK1045942A1 (en) 2002-12-20
IL149669A (en) 2006-06-11
JP2003516350A (en) 2003-05-13
NO20022739L (en) 2002-06-07
AU1949001A (en) 2001-06-18
WO2001041750A2 (en) 2001-06-14
KR100772854B1 (en) 2007-11-02
NZ519381A (en) 2004-04-30
EP1235570A2 (en) 2002-09-04
IL149669A0 (en) 2002-11-10
HUP0203309A3 (en) 2004-12-28
CN1409633A (en) 2003-04-09
CZ20021880A3 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
EP1243267A3 (en) Amoxycillin and clavulanate containing pharmaceutical formulation
RU2000104121A (en) THERAPEUTIC AND DIETIC COMPOSITIONS CONTAINING NECESSARY FATTY ACIDS AND BIOLOGICALLY ACTIVE DISULPHIDES
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
TW366286B (en) Flavour-masked pharmaceutical compositions
IL119627A0 (en) Controlled-release pharmaceutical preparations
WO2003039436A3 (en) Pharmaceutical compositions containing oxybutynin
AU1099288A (en) Drug delivery system and method of making the same
WO2001095899A3 (en) Pharmaceutical compositions comprising cannabidiol derivatives
MY130098A (en) Local drug delivery film for periodontal treatment
DE69521688D1 (en) PHARMACEUTICAL Brewing Preparations Containing Biodegradable Microcapsules For Controlled Release Of Active Ingredients
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
US6566389B1 (en) Therapeutic uses of melatonin
CA2396351A1 (en) New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
KR100420673B1 (en) Nasal administration to treat delayed nausea
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
ATE212550T1 (en) MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS
EP1197227A4 (en) Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
JO2296B1 (en) Substituted pyrroles
RU2003106417A (en) APPLICATION OF A VITAMIN COMBINATION FOR TREATMENT OF PRIMARY HEAD PAIN
CA2336711A1 (en) Blister containing a transdermal therapeutic system and a single dose form of administration
WO2013024487A1 (en) Anti- vitiligo composition
CZ5821U1 (en) Pharmaceutical composition intended for treating hemophilia and use of mestranol hormone
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201207